Xinxin Tian, Ph.D.
Director of Antibody Center, TIMBR/NIBS, Beijing
2019 Ph.D. Biochemistry and Molecular Biology, Peking University-Tsinghua University-National Institute Biological Sciences (PTN) Joint Graduate Program, China
2013 B.S. Pharmaceutical Engineering, Beijing University of Chemical Technology, China
2023- Director of Antibody Center, TIMBR/NIBS, Beijing
2019-2023 Postdoctoral Fellow, National Institute of Biological Sciences, Beijing
Publications （* co-first author）
1. Tian X*, Liu X*, Ding J, Wang F, Wang K, Liu J, Wei Z, Hao X, Li Y, Wei X, Zhang H, Sui J. An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice. Nat Biomed Eng 2023, 7 (1): 8-23.
2. Liu X*, Tian X*, Hao X, Zhang H, Wang K, Wei Z, Wei X, Li Y, Sui J. A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering. Mol Ther Oncolytics 2022, 27: 256-269.
3. Yang F, Zhao L, Wei Z, Yang Y, Liu J, Li Y, Tian X, Liu X, and Sui J. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects. J Immunol 2020, 205(8): 2156-2168
Antibody Center of National Institute of Biological Sciences, Beijing is dedicated to provide services related to development and evaluation of various types of antibodies (including polyclonal antibody, monoclonal antibody, single-chain Fv antibody, bi-specific antibody, and nanobody) for different experiments. We can also assist in design, production, and assessment of fusion proteins. Moreover, we have experience in developing and investigating antibodies targeting viruses, tumor-associated proteins, and immune checkpoints, and we look forward to cooperate with other research groups to develop therapeutic or diagnostic antibodies for other diseases.
